Microbiome-Based Neuropsychiatric Therapeutics (Psychobiotics) Market
完整報告名稱與涵蓋範圍
Microbiome-Based Neuropsychiatric Therapeutics (Psychobiotics) Market Size, Share & Trends Analysis Report, By Product Type (Prescription Live Biotherapeutic Products, Clinically Studied Probiotic and Postbiotic Formulations, Microbiome-Derived Small Molecules and Metabolites), By Indication (Depression and Anxiety, Autism Spectrum and Neurodevelopmental Disorders, Neurodegenerative Disease, Stress, Sleep and Cognitive Health), By Development Stage (Research and Preclinical, Clinical Development, Commercial (Supplement and Medical Food Channels)), By Distribution Channel, By Region, and Segment Forecasts, 2026-2035
報告摘要
The microbiome-based neuropsychiatric therapeutics market, often described as psychobiotics, covers products that act on the gut-brain axis to influence mood, cognition, neurodevelopment and neurodegeneration, spanning prescription live biotherapeutic products in development, clinically studied probiotic and postbiotic formulations sold as supplements or medical foods, and microbiome-derived small molecules. General gut-health probiotics without a neuropsychiatric claim are excluded. Commercial revenue today comes from evidence-backed supplement and medical food products; prescription product revenue is forecast from clinical progression rather than assumed.
Interest is grounded in mechanistic work linking microbial metabolites, vagal signalling and immune pathways to brain function, and in controlled trials reporting benefits on stress, mood and cognitive measures for specific strains. Drug developers are targeting autism-associated gastrointestinal and behavioural symptoms, treatment-resistant depression and neurodegeneration through defined consortia and metabolite-based medicines, while ingredient companies commercialise strains with clinical substantiation to differentiate in a crowded probiotic market. Regulatory clarity on live biotherapeutics, manufacturing consistency and the replication of early efficacy signals remain the principal uncertainties.
North America, Europe and Japan lead both consumer demand and clinical development, with South Korea and China expanding research programs. The competitive field combines microbiome drug developers, probiotic ingredient houses and science-led consumer brands.
The InsightAce study supplies US$ forecasts for all product type, indication, development stage and distribution channel and regional segments over 2026-2035, segment-level trend analysis, competitive landscape assessment and profiling of the leading companies.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Microbiome-Based Neuropsychiatric Therapeutics (Psychobiotics) Market Snapshot
Chapter 4. Global Microbiome-Based Neuropsychiatric Therapeutics (Psychobiotics) Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Product Type Estimates & Trend Analysis
5.1. Product Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Product Type:
5.2.1. Prescription Live Biotherapeutic Products
5.2.2. Clinically Studied Probiotic and Postbiotic Formulations
5.2.3. Microbiome-Derived Small Molecules and Metabolites
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. Indication & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
6.2.1. Depression and Anxiety
6.2.2. Autism Spectrum and Neurodevelopmental Disorders
6.2.3. Neurodegenerative Disease
6.2.4. Stress, Sleep and Cognitive Health
Chapter 7. Market Segmentation 3: By Development Stage Estimates & Trend Analysis
7.1. Development Stage & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Development Stage:
7.2.1. Research and Preclinical
7.2.2. Clinical Development
7.2.3. Commercial (Supplement and Medical Food Channels)
Chapter 8. Market Segmentation 4: By Distribution Channel Estimates & Trend Analysis
8.1. Distribution Channel & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Distribution Channel:
8.2.1. Pharmacies and Clinics
8.2.2. Retail and Online Supplements
Chapter 9. Microbiome-Based Neuropsychiatric Therapeutics (Psychobiotics) Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Axial Therapeutics, Inc.
11.2. Holobiome, Inc.
11.3. Bloom Science, Inc.
11.4. Seed Health, Inc.
11.5. Chr. Hansen (Novonesis)
11.6. Probi AB
11.7. ADM Biopolis
11.8. Kaleido Biosciences (Legacy Programs)
11.9. Vedanta Biosciences, Inc.
11.10. Enterome SA
11.11. 4D Pharma (Legacy Programs)
11.12. Microbiotica Ltd.
11.13. Finch Therapeutics Group, Inc.
11.14. dsm-firmenich AG
11.15. Lallemand Health Solutions
圖表清單 List of Tables & Figures
Table 1. Global Microbiome-Based Neuropsychiatric Therapeutics (Psychobiotics) Market Revenue Forecast by Product Type, 2026-2035 (US$ Mn)
Figure 1. Global Microbiome-Based Neuropsychiatric Therapeutics (Psychobiotics) Market Segmentation Overview
Table 2. Global Microbiome-Based Neuropsychiatric Therapeutics (Psychobiotics) Market Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 2. Global Microbiome-Based Neuropsychiatric Therapeutics (Psychobiotics) Market Share by Product Type, 2026 & 2035
Table 3. Global Microbiome-Based Neuropsychiatric Therapeutics (Psychobiotics) Market Revenue Forecast by Development Stage, 2026-2035 (US$ Mn)
Figure 3. Gut-Brain Axis Mechanisms Exploited by Psychobiotic Products
Table 4. Global Microbiome-Based Neuropsychiatric Therapeutics (Psychobiotics) Market Revenue Forecast by Distribution Channel, 2026-2035 (US$ Mn)
Figure 4. Global Microbiome-Based Neuropsychiatric Therapeutics (Psychobiotics) Market Share by Indication, 2026 & 2035
Table 5. North America Microbiome-Based Neuropsychiatric Therapeutics (Psychobiotics) Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Psychobiotic Pipeline and Commercial Products by Indication and Evidence Level
Table 6. Europe Microbiome-Based Neuropsychiatric Therapeutics (Psychobiotics) Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Microbiome-Based Neuropsychiatric Therapeutics (Psychobiotics) Growth Opportunity Analysis
Table 7. Asia Pacific Microbiome-Based Neuropsychiatric Therapeutics (Psychobiotics) Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Consumer Supplement Versus Prescription Pathway Economics for Microbiome CNS Products
Table 8. Latin America Microbiome-Based Neuropsychiatric Therapeutics (Psychobiotics) Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key Microbiome-Based Neuropsychiatric Therapeutics (Psychobiotics) Market Participants
Table 9. Middle East & Africa Microbiome-Based Neuropsychiatric Therapeutics (Psychobiotics) Market Revenue by Country, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們